Release Date: February 20, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you explain the rationale behind the $240 million to $250 million guidance for IBSRELA, which seems conservative given past growth rates? A: Mike Raab, President and CEO, explained that the guidance considers the typical first-quarter contraction in the IBS-C market, which historically sees a 10% decrease in scripts. The company wants to navigate this before adjusting guidance, ensuring confidence in the numbers provided.
Q: Regarding the $750 million peak sales target for XPHOZAH, does this include the Hatch-Waxman extension? A: Yes, Mike Raab confirmed that the $750 million target includes the Hatch-Waxman extension.
Q: Are there any expectations for licensing a new product this year? A: Mike Raab stated that while the objective is to build the pipeline, any announcements regarding new product licensing will depend on finding the right opportunity.
Q: How are physicians responding to the new reimbursement dynamics for XPHOZAH, and are they prescribing it as they did in 2024? A: Eric Foster, Chief Financial and Operations Officer, noted that while it's too early to determine if volumes have bottomed out, the message of continued access is well received. The company is ensuring that the processes for patient access are working as planned.
Q: What strategies are in place to ensure Medicare patients continue to access XPHOZAH? A: Eric Foster highlighted the Ardelyx Assist program, which helps manage patient access regardless of payer coverage. The company is expanding its field-based access manager team to support this effort.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.